Pen-Type Insulin Devices: Industry Outlook, Mechanical vs. Digital Delivery & Patient Preferences
公開 2026/04/01 16:48
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Reusable Insulin Injection Pen - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". In diabetes management, ensuring consistent, precise insulin delivery while supporting patient autonomy remains a fundamental clinical objective. Healthcare providers and patients face challenges in achieving accurate dosing, maintaining medication adherence, and managing the practical aspects of long-term injectable therapy. This report quantifies the market trajectory of reusable insulin injection pens—pen-type injection devices engineered to address these challenges through precise quantitative dosing, cartridge-based design, and user-friendly operation.
The global market for Reusable Insulin Injection Pen was estimated to be worth US$ 4,671 million in 2025 and is projected to reach US$ 7,030 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global production of reusable injection pens reached 118,546 million units, with an average selling price of US$0.14 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097950/reusable-insulin-injection-pen
Defining the Technology: Cartridge-Based Precision Delivery
Pen-type injection devices combine medication and an injection device into one unit, offering key advantages such as precise, quantitative injection, self-medication, safety, and convenience, while avoiding the risk of accidentally breaking a glass syringe. These devices precisely meet the needs of patients with diabetes, weight loss, and other long-term medication needs, and are gradually becoming a mainstream injection solution. Reusable insulin pens consist of a pen and an insulin cartridge. Once the cartridge is depleted, the pen can be replaced with a new one, allowing for repeated use. Reusable pens are a mainstream injection solution for diabetic patients, offering the economic and environmental benefits of reduced waste compared to disposable alternatives.
Market Segmentation: Mechanical, Electric, and Optical Force Systems
The Reusable Insulin Injection Pen market is segmented by dosing mechanism into mechanical force, electric force, and optical force systems. Mechanical force devices—utilizing spring-loaded or manual dial-and-dose mechanisms—represent the largest segment, favored for their simplicity, reliability, independence from battery power, and lower cost. These devices have been the standard for decades and remain widely prescribed.
Electric force devices represent the fastest-growing segment, offering programmable dosing, digital dose memory, and connectivity features that support adherence tracking and integration with diabetes management applications. These devices appeal to tech-enabled patients and those requiring precise dose adjustments. Optical force devices represent an emerging segment with potential for enhanced precision and user feedback, though current market penetration remains limited.
Application Landscape: Hospital & Clinic, Retail Pharmacies, and Online Channels
From an application perspective, the market serves three primary distribution channels. Hospital and clinic channels represent the largest segment, with reusable pens prescribed and dispensed through healthcare facilities where patient education and initial training occur. Retail pharmacies represent a significant and growing segment, supporting ongoing patient access and refill services for chronic disease management. Online channels represent the fastest-growing segment, driven by consumer preference for direct purchasing, subscription services, and the expansion of e-commerce platforms for diabetes supplies.
Competitive Landscape: Global Diabetes Care Leaders and Regional Specialists
The competitive landscape features established global diabetes care leaders with decades of market presence. Novo Nordisk dominates the premium segment, leveraging its integrated portfolio of insulin products and proprietary reusable pen platforms. Eli Lilly and Sanofi command significant market share with established reusable pen offerings tied to their insulin portfolios. Ypsomed and Owen Mumford represent specialized device manufacturers with expertise in injection technology, offering reusable pens compatible with multiple insulin brands.
A robust Asian manufacturing ecosystem has emerged, with Tonghua Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, Jiangsu Delfu Medical Device, Wanhai Medical, Phray Technology, Shanghai Umitai Medical Technology, Shandong Kangli Medical Equipment Technology, Gangan Medical Technology Jiangsu, and Lepu Medical Technology capturing market share through cost-competitive offerings and distribution networks in China and emerging markets.
Industry Deep-Dive: Diabetes Prevalence and Adherence Optimization
Over the past six months, the industry has witnessed sustained demand driven by three converging factors. First, the continued global expansion of diabetes prevalence has expanded the addressable market. According to the International Diabetes Federation, over 540 million adults currently live with diabetes, with projections exceeding 640 million by 2030. This expanding patient population drives sustained demand for insulin delivery devices.
Second, the emphasis on treatment adherence has intensified focus on user-friendly delivery systems. A recent study from a large academic diabetes center revealed that patients using reusable insulin pens demonstrated 15% higher adherence rates compared to vial-and-syringe users, with significant improvements in glycemic control attributed to ease of use, dose accuracy, and reduced injection anxiety.
Third, the expansion of glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and weight management has created additional demand for reusable pen platforms. These therapies, increasingly prescribed for both type 2 diabetes and obesity, utilize similar pen delivery systems, expanding the market beyond traditional insulin applications.
Exclusive Insight: Divergence Between Branded and Unbranded Reusable Pens
A distinct adoption pattern emerges when comparing reusable pen platforms across market segments. Branded reusable pens—designed for specific insulin products and distributed through pharmaceutical company channels—represent the largest segment. These devices benefit from integrated marketing, formulary placement, and patient loyalty to specific insulin brands.
Unbranded or "universal" reusable pens—compatible with multiple insulin cartridge formats—represent a growing segment, particularly in markets where cost containment and device interchangeability are prioritized. These devices appeal to payers seeking to reduce costs and patients using multiple insulin types.
This divergence has strategic implications for manufacturers. Those focusing on branded pens must maintain strong relationships with pharmaceutical partners and invest in device-format integration. Those targeting the universal segment must prioritize broad cartridge compatibility, ease of use, and cost competitiveness.
Technical Barriers and Innovation Frontiers
Ensuring dose accuracy and consistency across thousands of actuations remains a technical priority. Reusable pens must maintain precision over extended service life, with mechanisms subject to wear. Manufacturers are investing in durability testing and high-grade materials to ensure long-term reliability.
Another frontier is the integration of digital health features, including dose tracking, dose memory, and connectivity with continuous glucose monitoring (CGM) systems. These connected devices offer enhanced diabetes management capabilities, supporting data-informed dose adjustments and improved clinical outcomes.
Future Outlook: Sustained Growth Through Diabetes Expansion and Digital Integration
Looking toward 2032, the market is poised for sustained growth at a 6.1% CAGR, reaching US$7.0 billion. Key catalysts include continued global expansion of diabetes prevalence, increasing adoption of GLP-1 therapies for diabetes and weight management, and integration of digital health features that enhance adherence and outcomes. Manufacturers that can deliver reliable, user-friendly reusable pens with broad therapeutic compatibility and digital connectivity will capture disproportionate market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Reusable Insulin Injection Pen was estimated to be worth US$ 4,671 million in 2025 and is projected to reach US$ 7,030 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global production of reusable injection pens reached 118,546 million units, with an average selling price of US$0.14 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097950/reusable-insulin-injection-pen
Defining the Technology: Cartridge-Based Precision Delivery
Pen-type injection devices combine medication and an injection device into one unit, offering key advantages such as precise, quantitative injection, self-medication, safety, and convenience, while avoiding the risk of accidentally breaking a glass syringe. These devices precisely meet the needs of patients with diabetes, weight loss, and other long-term medication needs, and are gradually becoming a mainstream injection solution. Reusable insulin pens consist of a pen and an insulin cartridge. Once the cartridge is depleted, the pen can be replaced with a new one, allowing for repeated use. Reusable pens are a mainstream injection solution for diabetic patients, offering the economic and environmental benefits of reduced waste compared to disposable alternatives.
Market Segmentation: Mechanical, Electric, and Optical Force Systems
The Reusable Insulin Injection Pen market is segmented by dosing mechanism into mechanical force, electric force, and optical force systems. Mechanical force devices—utilizing spring-loaded or manual dial-and-dose mechanisms—represent the largest segment, favored for their simplicity, reliability, independence from battery power, and lower cost. These devices have been the standard for decades and remain widely prescribed.
Electric force devices represent the fastest-growing segment, offering programmable dosing, digital dose memory, and connectivity features that support adherence tracking and integration with diabetes management applications. These devices appeal to tech-enabled patients and those requiring precise dose adjustments. Optical force devices represent an emerging segment with potential for enhanced precision and user feedback, though current market penetration remains limited.
Application Landscape: Hospital & Clinic, Retail Pharmacies, and Online Channels
From an application perspective, the market serves three primary distribution channels. Hospital and clinic channels represent the largest segment, with reusable pens prescribed and dispensed through healthcare facilities where patient education and initial training occur. Retail pharmacies represent a significant and growing segment, supporting ongoing patient access and refill services for chronic disease management. Online channels represent the fastest-growing segment, driven by consumer preference for direct purchasing, subscription services, and the expansion of e-commerce platforms for diabetes supplies.
Competitive Landscape: Global Diabetes Care Leaders and Regional Specialists
The competitive landscape features established global diabetes care leaders with decades of market presence. Novo Nordisk dominates the premium segment, leveraging its integrated portfolio of insulin products and proprietary reusable pen platforms. Eli Lilly and Sanofi command significant market share with established reusable pen offerings tied to their insulin portfolios. Ypsomed and Owen Mumford represent specialized device manufacturers with expertise in injection technology, offering reusable pens compatible with multiple insulin brands.
A robust Asian manufacturing ecosystem has emerged, with Tonghua Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, Jiangsu Delfu Medical Device, Wanhai Medical, Phray Technology, Shanghai Umitai Medical Technology, Shandong Kangli Medical Equipment Technology, Gangan Medical Technology Jiangsu, and Lepu Medical Technology capturing market share through cost-competitive offerings and distribution networks in China and emerging markets.
Industry Deep-Dive: Diabetes Prevalence and Adherence Optimization
Over the past six months, the industry has witnessed sustained demand driven by three converging factors. First, the continued global expansion of diabetes prevalence has expanded the addressable market. According to the International Diabetes Federation, over 540 million adults currently live with diabetes, with projections exceeding 640 million by 2030. This expanding patient population drives sustained demand for insulin delivery devices.
Second, the emphasis on treatment adherence has intensified focus on user-friendly delivery systems. A recent study from a large academic diabetes center revealed that patients using reusable insulin pens demonstrated 15% higher adherence rates compared to vial-and-syringe users, with significant improvements in glycemic control attributed to ease of use, dose accuracy, and reduced injection anxiety.
Third, the expansion of glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and weight management has created additional demand for reusable pen platforms. These therapies, increasingly prescribed for both type 2 diabetes and obesity, utilize similar pen delivery systems, expanding the market beyond traditional insulin applications.
Exclusive Insight: Divergence Between Branded and Unbranded Reusable Pens
A distinct adoption pattern emerges when comparing reusable pen platforms across market segments. Branded reusable pens—designed for specific insulin products and distributed through pharmaceutical company channels—represent the largest segment. These devices benefit from integrated marketing, formulary placement, and patient loyalty to specific insulin brands.
Unbranded or "universal" reusable pens—compatible with multiple insulin cartridge formats—represent a growing segment, particularly in markets where cost containment and device interchangeability are prioritized. These devices appeal to payers seeking to reduce costs and patients using multiple insulin types.
This divergence has strategic implications for manufacturers. Those focusing on branded pens must maintain strong relationships with pharmaceutical partners and invest in device-format integration. Those targeting the universal segment must prioritize broad cartridge compatibility, ease of use, and cost competitiveness.
Technical Barriers and Innovation Frontiers
Ensuring dose accuracy and consistency across thousands of actuations remains a technical priority. Reusable pens must maintain precision over extended service life, with mechanisms subject to wear. Manufacturers are investing in durability testing and high-grade materials to ensure long-term reliability.
Another frontier is the integration of digital health features, including dose tracking, dose memory, and connectivity with continuous glucose monitoring (CGM) systems. These connected devices offer enhanced diabetes management capabilities, supporting data-informed dose adjustments and improved clinical outcomes.
Future Outlook: Sustained Growth Through Diabetes Expansion and Digital Integration
Looking toward 2032, the market is poised for sustained growth at a 6.1% CAGR, reaching US$7.0 billion. Key catalysts include continued global expansion of diabetes prevalence, increasing adoption of GLP-1 therapies for diabetes and weight management, and integration of digital health features that enhance adherence and outcomes. Manufacturers that can deliver reliable, user-friendly reusable pens with broad therapeutic compatibility and digital connectivity will capture disproportionate market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ